High chemo dosage improves survival for AML patients

12/5/2008 | Yahoo!

Research shows a higher dose of the chemotherapy drug daunorubicin increased median survival rates for patients with previously untreated acute myeloid leukemia, when compared with using the standard dosage. Patients in the high-dose group had overall survival of 23.7 months, compared to 15.1 months for patients in the standard-dose group.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ
Health Plan CEO – Oregon
Trillium Community Health Plan
Eugene, OR
Director of Operations - GBS
Mayo Clinic
Rochester, MN